

RESEARCH

Open Access

# Membrane topology analysis of HIV-1 envelope glycoprotein gp41

Shujun Liu<sup>1†</sup>, Naoyuki Kondo<sup>1,2,3†</sup>, Yufei Long<sup>1</sup>, Dan Xiao<sup>1</sup>, Aikichi Iwamoto<sup>3</sup>, Zene Matsuda<sup>1,2\*</sup>

## Abstract

**Background:** The gp41 subunit of the HIV-1 envelope glycoprotein (Env) has been widely regarded as a type I transmembrane protein with a single membrane-spanning domain (MSD). An alternative topology model suggested multiple MSDs. The major discrepancy between the two models is that the cytoplasmic Kennedy sequence in the single MSD model is assigned as the extracellular loop accessible to neutralizing antibodies in the other model. We examined the membrane topology of the gp41 subunit in both prokaryotic and mammalian systems. We attached topological markers to the C-termini of serially truncated gp41. In the prokaryotic system, we utilized a green fluorescent protein (GFP) that is only active in the cytoplasm. The tag protein (HaloTag) and a membrane-impermeable ligand specific to HaloTag was used in the mammalian system.

**Results:** In the absence of membrane fusion, both the prokaryotic and mammalian systems (293FT cells) supported the single MSD model. In the presence of membrane fusion in mammalian cells (293CD4 cells), the data obtained seem to support the multiple MSD model. However, the region predicted to be a potential MSD is the highly hydrophilic Kennedy sequence and is least likely to become a MSD based on several algorithms. Further analysis revealed the induction of membrane permeability during membrane fusion, allowing the membrane-impermeable ligand and antibodies to cross the membrane. Therefore, we cannot completely rule out the possible artifacts. Addition of membrane fusion inhibitors or alterations of the MSD sequence decreased the induction of membrane permeability.

**Conclusions:** It is likely that a single MSD model for HIV-1 gp41 holds true even in the presence of membrane fusion. The degree of the augmentation of membrane permeability we observed was dependent on the membrane fusion and sequence of the MSD.

## Background

The envelope glycoprotein (Env) of human immunodeficiency virus type-1 (HIV-1) plays a critical role in the early stage of HIV-1 infection. Env is synthesized as a precursor protein, gp160 [1,2], and processed into gp120 and gp41 during transport from the endoplasmic reticulum to Golgi network [3,4]. The gp120 subunit determines host range through its recognition of the receptor and co-receptor complex. The transmembrane protein gp41 mediates the membrane fusion between the host and viral membranes. It is composed of an ectodomain (extracellular domain), a cytoplasmic domain, and a

transmembrane domain. The ectodomain has coiled-coil-forming heptad repeats essential for membrane fusion. The cytoplasmic domain contains three amphipathic helices called the lentiviral lytic peptide (LLP) 1, 2 and 3. The LLP-1 and LLP-2 portions have a high hydrophobic moment common to membrane-lytic peptides [5-9].


The transmembrane domain of gp41 was first deduced from the hydropathy plot of Env as a hydrophobic domain [10]. This transmembrane domain, herein referred to as the membrane-spanning domain (MSD), is composed of 23 highly conserved amino acid residues corresponding to amino acid residues 684 to 706 in the HXB2 strain (Figure 1A, B). An *in vitro* translation study in the presence of microsomal membranes suggested that HIV-1 Env has one MSD [11], as predicted by the hydropathy plot. In that study, the C-terminus of

\* Correspondence: [zmatsuda@ims.u-tokyo.ac.jp](mailto:zmatsuda@ims.u-tokyo.ac.jp)

† Contributed equally

<sup>1</sup>China-Japan Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing 100101, P. R. China

Full list of author information is available at the end of the article



gp41 was assigned to the cytoplasmic side of the cellular membrane [11], hence the gp41 subunit is regarded as a type I membrane protein with a single MSD. Other studies provided data consistent with this single MSD model. For example, two cysteine residues for palmitoylation are located in the cytoplasmic domain: one in the middle of LLP-1 (Cys-838) and the other at the upstream of LLP-2 (Cys-765) [12]. The internalization motif, YXXL (Tyr-769 to Leu-772), at the beginning of LLP-2 [13] also maps to the cytoplasmic domain of the single MSD model.

On the other hand, the mapping of the epitopes for neutralizing antibodies called into question the single MSD model. Some of the epitopes were mapped to the cytoplasmic region which contained the amino acid sequence known as the Kennedy sequence (<sup>724</sup>PRGPD RPEGIEEGGERDRDRS<sup>745</sup>) [14-16] (Figure 1A). Furthermore, a report using an antibody raised against the LLP-2 portion revealed target binding during membrane fusion when added extracellularly [17]. As antibodies in general are not expected to cross intact membranes, an alternative membrane topology model of gp41 has been suggested in order to assign the mapped epitopes in the extracellular region [16] (Figure 1C). In this alternative model multiple MSDs were proposed

because the C-terminus was assumed to be in the cytoplasm. Furthermore, the transmembrane portion of the single MSD model is expected to cross the membrane twice and one of LLPs, LLP2, is a putative third MSD (Figure 1C).

Several studies of the transmembrane portion of the single MSD model showed that it plays a critical role in the modulation of the membrane fusion process, which is an essential step of the HIV-1 life cycle [18-24]. Therefore analysis of the topology and structures of the transmembrane domain of gp41 is critical for our understanding of the mechanism of the membrane fusion. Furthermore the location of the neutralizing epitopes for antibodies is vital for a vaccine development.

In this study we reexamined gp41 topology in two different biological systems; prokaryotic and mammalian systems. The results of prokaryotic and mammalian systems without membrane fusion supported the single MSD model. The results obtained in the mammalian system in the presence of membrane fusion seem to support a transient alteration of the membrane topology of gp41. It is important, however, to note that the effect of the induction of membrane permeability during HIV-1 Env-mediated membrane fusion cannot be excluded. The induction of membrane permeability was reduced by replacing the HIV-1 MSD with that of a foreign protein, CD22.

## Methods

### Plasmid construction

All PCR amplicons were first cloned into pCR4Blunt-TOPO using the TOPO cloning kit (Invitrogen, Carlsbad, CA) and sequences were verified.


For the topology analysis in the prokaryotic system, the expression vector pKMal-p2e was generated. pKMal-p2e has a kanamycin resistance gene derived from pK18 instead of  $\beta$ -lactamase in the context of pMal-p2e (NEB, Beverly, MA). The oligonucleotide adaptor generated by annealing the following two oligonucleotides: 5'-GTACCG AACAAT TACAC AAGCTTC GGATC CTCTAGA GTCGAC CTGCAG GC G-3' and 5'-AGCTC GC CTGCAG GTCGAC TCTAGA GGATCC GAAGCT TGTGTA ATTGTT CG -3' were inserted into pKMal-p2e to modify the multiple cloning site. This modified vector was named as mpKMal-p2e. The green fluorescent protein (GFP) gene as the reporter for the membrane topology was prepared by PCR using GFPopt<sub>1-11</sub> in pCR4Blunt-TOPO [25] as the template with 5'-GAC TCTAGA ATGGTG AGCAAG GGCGAG GAGC-3' and 5'-GCACTG CAGTCA GGTGAT GCCGGC GGCGT-3' as the forward and reverse primer, respectively, and cloned into mpKMal-p2e vector using *Xba*I and *Pst*I sites. The generated vector was named as mpKMalp2e-GFP (Table 1).

**Table 1 Plasmids used in this study**

Plasmids	Description
For prokaryotic system	
mpKMalp2e-GFP	Multiple cloning site-modified pMalp2e containing <i>Kan<sup>R</sup></i> and Green fluorescent protein genes
mpKMalp2e-gp41-1-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at W666
mpKMalp2e-gp41-2-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at I682
mpKMalp2e-gp41-3-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at G694
mpKMalp2e-gp41-4-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at R725
mpKMalp2e-gp41-5-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at R747
mpKMalp2e-gp41-6-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at R788
mpKMalp2e-gp41-7-GFP	mpKMalp2e-GFP with C-terminally truncated gp41 at A819
mpKMalp2e-gp41-8-GFP	mpKMalp2e-GFP with full-length gp41
optGFP <sub>1-11</sub> /pET-47md	Modified pET-47b with modified super folder GFP
For mammalian system	
pHIVenv-Halo	The CMV promoter driven mammalian expression vector containing HaloTag gene
pHIVenv-gp41-4-Halo	pHIVenv-Halo containing Env with C-terminally truncated gp41 at R725
pHIVenv-gp41-5-Halo	pHIVenv-Halo containing Env with C-terminally truncated gp41 at R747
pHIVenv-gp41-6-Halo	pHIVenv-Halo containing Env with C-terminally truncated gp41 at R788
pHIVenv-gp41-7-Halo	pHIVenv-Halo containing Env with C-terminally truncated gp41 at A819
pHIVenv-gp41-8-Halo	pHIVenv-Halo containing full-length Env
pHIVenv-gp41-5	Halo-deleted pHIVenv-gp41-5-Halo
pHIVenv-gp41-8	Halo-deleted pHIVenv-gp41-8-Halo
pHIVenv-CD22-gp41-5	The gp41 MSD replaced pHIVenv-gp41-5 with the MSD of CD22
pHIVenv-CD22-gp41-8	The gp41 MSD replaced pHIVenv-gp41-8 with the MSD of CD22
pHook-Halo-GPI	The expression vector of the GPI anchored-HaloTag
pKcTac-Halo	The expression vector of Tac antigen of IL-2 receptor fused with C-terminal HaloTag
pKcTac-FLAG	pKcTacHalo vector whose HaloTag was replaced with 3xFLAG

This plasmid was used for the negative control for the experiment.

The near full-length gp41 gene derived from the HIV-1 HXB2 strain was amplified by PCR using pGEM7zf(+)-NB [23] as a template with 535fACC651 (Met):5'-AGTGGT ACCGAT GACGCT GACGGT ACAGGC CAGA-3' and 856 rXbaI: 5'-GTCTCT AGA-TAG CAAAAT CCTTTC CAAGCC CTG-3' as the forward and the reverse primer, respectively. The plasmid that harbors near full-length gp41 in pCR4blunt-TOPO was named as pEnv-HXB2gp41. For the construction of the gp41 mutants, the C-termini were serially truncated, (see Table 1 and Figure 1A), the various gp41 fragments were amplified by PCR using pEnv-HXB2gp41 as a template, with the oligonucleotide 535fACC651 as a forward primer, and the corresponding reverse primer designed for each truncation site. These truncated gp41 fragments were cloned into the vector mpKMalp2e-GFP with *Hind*III, which is present in the gp41 gene, and *Xba*I at the 5' and 3' terminus, respectively of the fragments. Figure 2A shows the resulting mpKMalp2e-gp41-GFP fusion constructs. The plasmid, optGFP<sub>1-11</sub>/pET-47md [26]




**Figure 2 Constructs used to express recombinant gp41 in the *E. coli* system.** (A) The expression vectors used in this study. The *env* gene is derived from HIV-1 HXB2 strain. gp41 starts amino acid 636 and ends with the various C-terminal positions as indicated in Fig. 1A. The schema below the plasmid map shows the components of the recombinant proteins. The truncated gp41 is preceded by maltose binding protein (MBP) and followed by the topological reporter, green fluorescent protein (GFP). The nomenclatures are as follows: lacI, lacI repressor gene; pTac, a hybrid promoter between trp and lac promoters; CT, cytoplasmic tail; AmpR, ampicillin resistant gene; f1ori, replication origin of f1; pBR322ori, replication origin of pBR322 plasmid. (B) Expression of the recombinant proteins. The immunoblotting of bacterial lysates probed with the anti-GFP antibody is shown. The name on the top of each lane indicates the expression vector used (see Table 1).

that expresses GFP in the cytoplasm was used as a positive control.

The Halo7 gene was amplified by PCR using pFC14k-HaloTag7 (Promega, Madison, WI) as a template, with 5'-GTCGAC GCGGT GCGGT AGCGGA TCCGAA ATCGGT ACTG-3' and 5'-GGTACC TTAACC GGAAAT CTCCAG AG-3' oligonucleotides as the forward and the reverse primer, respectively. The forward primer contained a *Sall* site and short linker sequence, Gly<sub>4</sub>Ser, between the *Sall* site and Halo7 coding region. The reverse primer included an *Acc65I* site. The amplicon was inserted into the pHIVenvOPT vector, containing an envelope gene based on HXB2 strain that was optimized for human codon usage. The vector generated was named as pHIVenv-Halo (Figure 3A). To construct the truncation gp41 mutants for the mammalian analyses, five different positions were chosen as the

C-terminal truncation points (Figure 1A and Table 1). The fragments of truncated *env* from *XmnI* to each termination codon were amplified by PCR using pHIVenvOPT as a template with 5'-GCTAGC AAATTA AGAGAAC-3' including the *Sall* site as the forward primer and the corresponding oligonucleotides at the truncated sites as the reverse primers, respectively. The *env* fragments were inserted into pHIVenv-Halo (Table 1). For the construction of pHIVenv-gp41-5 and pHIVenv-gp41-8, stop codon-containing oligonucleotides generated by annealing 5'-TCGACTGATGAG-3' with 5'-GTACCTCATCAG-3' was replaced with HaloTag gene to delete HaloTag. The Env expression vector with the MSD of CD22 [27] was constructed using PCR and replacement of the original MSD with the MSD of CD22. As for the control plasmids, two other expression vectors were constructed. The glycosylphosphatidylinositol (GPI)-anchored HaloTag gene was constructed as a marker for surface expression of HaloTag (Halo-GPI in Figure 3A and Table 1). The GPI signal is derived from decay accelerating factor of human origin [28]. A Tac antigen, which is alpha subunit of Interleukin-2 receptor and is a single transmembrane protein [29], was fused with HaloTag gene at the C-terminus (Tac-Halo in Figure 3A and Table 1). This construct was used for the expression of the HaloTag protein in the cytoplasm. A derivative of this expression vector for Tac with a FLAG epitope at its C-terminus (Tac-FLAG) was generated by replacing the HaloTag sequence with that for 3xFLAG tag.



### Expression of GFP-fused gp41 proteins and measurement of GFP fluorescence intensity

*E. coli* strain BL21 transformed with mpKMal-p2e carrying serially truncated gp41 genes fused to GFP reporter was grown overnight at 22°C in TAG medium (10 g/L Tryptone, 5 g/L NaCl, 5 g/L Glucose, 7 g/L K<sub>2</sub>HPO<sub>4</sub>, 3 g/L KH<sub>2</sub>PO<sub>4</sub>, 1 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.47 g/L Sodium Citrate) with 50 µg/ml kanamycin. The overnight bacterial culture was diluted 1:50 in 4 ml TAG fresh medium containing 50 µg/ml kanamycin and growth was continued at 22°C until the OD<sub>600</sub> reached 0.2. Cells were grown for overnight in the presence of 0.1 mM IPTG. Subsequently, one ml aliquot of culture was collected and resuspended in 0.5 ml of PBS buffer and the GFP fluorescence intensity was measured by flow cytometry using a FACS Calibur (BD Biosciences, Mississauga, ON). At the same time, another 1 ml aliquot of culture was dispensed for SDS-PAGE and immunoblotting analysis.

### Mammalian cell culture, transfection, labeling, and imaging

The 293FT cells (Invitrogen, Carlsbad, USA) or 293CD4 cells (293 cells constitutively expressing human CD4) [23]

were grown in 96-well Matriplates (GE Healthcare, Piscataway, NJ) with Dulbecco's modified Eagle medium (DMEM; Sigma, St. Louis, USA) supplemented with 10% FBS (Hyclone Labs., Logan, UT). In the case of 293FT, 5 µg/ml Geneticine (GiBco, Grand Island, USA) was further supplied. Cells were grown at 37°C in 5% CO<sub>2</sub> incubator.

DNA transfection of mammalian cells was performed using Fugene HD (Roche, Indianapolis, USA; Fugene HD (µl): DNA(µg): DMEM(µl) = 5:2:200). The transfection mix was incubated for 15 mins at room temperature prior to addition to the cell culture in a drop-wise manner (10 µl per well). After certain hours of transfection the transfected cells were subjected for further analyses as described below.

At the indicated time after transfection, the transfected cells were probed with HaloTag ligands. The starting time point of labeling after transfection was different for different experiments involving a different set of cells and vectors (see the Results section). The labeling was performed as suggested by the manufacturer (Promega). Briefly, the transfected live cells were labeled for 15 mins at 37°C with 1 µM of HaloTag ligand Alexa Fluor 488 (AF488), a membrane-impermeable ligand, or Oregon Green (OG), a membrane permeable ligand, respectively. After labeling, the cells were rinsed three times with 200 µl prewarmed DMEM plus 10% FBS and subsequently incubated at 37°C with 5% CO<sub>2</sub> for 30 mins. The medium was changed with fresh warm DMEM plus 10% FBS, then images were captured using a confocal microscope (Olympus FluoView FV1000, Tokyo, Japan).

Immunofluorescent staining assay using the anti-FLAG monoclonal antibody (Sigma) was performed to detect the FLAG-tagged proteins as below. Following the fixation of the transfected cells with 2% paraformaldehyde at 25°C for 5 mins, the anti-FLAG antibody (1/200 in 0.5% BSA and PBS) was used as the first antibody. After incubating at room temperature for 1 h, the cells were rinsed 3 times with 200 µl prewarmed PBS plus 0.5% BSA and subsequently incubated with anti-mouse antibody conjugated with AlexaFluor 488 (Invitrogen) (1/200 in 0.5% BSA and PBS) at room temperature for 1 h. The images were captured using a confocal microscope (Olympus).

To evaluate the cell viability, staining with propidium iodide (PI) [30] was used. In the case of co-labeling with the HaloTag ligands, staining with AF488 was performed first, then PI staining for 15 min at room temperature with a final concentration of 2.5µg/ml followed. The cells were rinsed two times with PBS and images were analyzed as described above. In the case of co-staining with anti-FLAG monoclonal antibodies, PI staining was performed first, followed by labeling with the anti-FLAG monoclonal antibody.

To mimic the effect of the conformational changes of gp120 after its binding to the CD4 receptor, soluble

CD4 was added to the 293FT cells transfected with HIV-1 Env expression vectors. The soluble CD4 protein (final concentration: 0.1 µM) was kept in the medium since immediately after transfection.

#### Syncytia formation assay

A syncytia formation assay was performed by transfecting the HIV-1 Env expression vectors (listed as For mammalian system in Table 1) into the 293CD4 cells. The cells were transfected when they were about 50% confluent. At 48 h after transfection, the images were captured with IN Cell analyzer 1000 (GE Healthcare, Uppsala, Sweden). The fusion activity of Halo-fused Env was evaluated by counting 300 nuclei in total after staining with 2 µM Hoechst and determining the percentage of nuclei included in syncytia.

#### Immunoblot analysis

Bacterial cultures (1 ml) were harvested and resuspended in 50 µl SDS-PAGE loading buffer (2% SDS, 2 mM DTT, 10% glycerol, 50 mM Tris-HCl, pH6.8, 0.01% Bromo phenol blue). The mixture was kept for 10 mins at 95°C and subjected to centrifugation (20,000 g, 4°C) with MX-301 (Tomy, Japan) to remove the pellets. Whole cell lysates (2 µl) were resolved using a 5-20% gradient SDS polyacrylamide gel (DRC, Tokyo, Japan). The proteins were transferred to the PVDF membrane and probed with 15,000-fold diluted anti-GFP antibody (Santa Cruz Biotechnology, Santa Cruz, USA) for 1 h at room temperature. Anti-mouse antibody (GE healthcare), diluted by 5,000-fold, was used as the secondary antibody. The signal was developed by streptavidin-biotinylated horseradish peroxidase complex (GE healthcare) and the chemiluminescence reagents (Roche), and detected by LAS3000 (Fuji).

The transfected 293FT cells grown in 10-cm dishes as described above were collected and centrifugated (5,000 g, 4°C) with MX-301. The cell pellet was lysed with 250µl of RIPA lysis buffer [50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.1% SDS] and then centrifuged (MLA-130 rotor, 100,000rpm, 30 mins, 4°C) with Beckman Optima™Max Ultracentrifuge. The supernatant (20 µl) was treated with the same method as described above. The protein bands on the PVDF membrane were developed as described above, except for the 500-fold diluted anti-Halo pAb (Promega) and 5000-fold diluted anti-rabbit antibody (GE healthcare) which were used as the primary and secondary antibodies, respectively.

## Results

### Topology mapping of gp41 using GFP as a reporter in a prokaryotic system

We first employed the well-established prokaryotic topological analysis using GFP as a reporter [31,32]. If

GFP is located in the cytoplasm it folds into an active form, whereas when it is translocated into the periplasm it is non-functional [31]. The periplasm-targeted maltose-binding protein was placed at the N-terminus of the gp41 portion to be tested, and then GFP, a topological reporter, was fused to the C-terminus of the gp41 fragment (Figure 2A). The series of gp41 proteins truncated at the different C-terminal positions were tested (Figure 1A and Table 1). The N-terminus of gp41 portion included was fixed at the position of 636th amino acid close to the predicted MSD (Figure 1A dotted line), because there is little controversy on the beginning of the MSD itself.

After transformation of *E. coli* with one of the plasmids, the expression of the recombinant protein was evaluated by immunoblotting using an anti-GFP antibody and the results are shown in Figure 2B. The levels of protein expression with mpKMalp2e-gp41-1-GFP, mpKMalp2e-gp41-2-GFP, and mpKMalp2e-gp41-3-GFP, were low (Figure 2B), and we did not analyze these constructs further. The rest of constructs each expressed a comparable amount of the fusion protein of about 100kD (Figure 2B). The fluorescence intensities of GFP at 530 nm of *E. coli* induced for the expression of the fusion proteins were measured by a flow cytometry. Compared with the negative control that expresses GFP in the periplasm (mpKmalp2e-GFP), the GFP intensity adjusted by the cell density was significantly higher for mpKMalp2e-gp41-4-GFP, mpKMalp2e-gp41-5-GFP, mpKMalp2e-gp41-6-GFP mpKMalp2e-gp41-7-GFP and mpKMalp2e-gp41-8-GFP (Table 2). This suggested that GFP attached at the position 4 to 8 lies in the cytoplasm. Interestingly, there was no significant difference in the GFP fluorescent intensity adjusted by the level of the expression for mpKMalp2e-gp41-4-GFP, mpKMalp2e-gp41-5-GFP, mpKMalp2e-gp41-6-GFP, mpKMalp2e-gp41-7-GFP and mpKMalp2e-gp41-8-GFP. These data suggested that there was no topological shift of GFP reporter in these regions; therefore the Kennedy sequence and LLP regions are not exposed to the

periplasmic region. These results are consistent with the single MSD model of gp41 (Figure 1B).

#### Expression of HaloTag-attached HIV-1 Env in mammalian cells

Although the bacterial system is quick and informative, eukaryote specific post-translational modifications and/or the difference in the composition of lipids in the membrane may affect the topology of gp41. Therefore, HIV-1 Env with the C-terminus of gp41 linked to HaloTag was expressed in mammalian cells (Figure 3A). The HaloTag is a 33 kDa protein designed to covalently bind to its membrane-permeable/impermeable ligands conjugated with a fluorescent chromophore [33]. Based on the previous published results [11] and our own results of the prokaryotic system (see above), we focused on the analysis of the region after the predicted MSD of the single MSD model (truncation positions 4-8 in Figure 1A). The GPI-anchored HaloTag protein (Halo-GPI) and the HaloTag attached to the C-terminus of the Tac antigen after MSD (Tac-Halo) were made as the controls for the extracellular and intracellular positioning of HaloTags, respectively (Figure 3A and Table 1). Expression of HaloTag-attached envelope proteins was confirmed by immunofluorescence analysis with anti-gp120 antibody (data not shown) and immunoblotting analysis with anti-Halo antibodies (Figure 3B). The bands around 130-170kD and 40-55kD for pHIVenv-gp41-Halo are HaloTag-attached gp160 and gp41, respectively.

The membrane fusion capacity of these mutants was examined with a syncytia formation assay by transfecting the expression vector into 293CD4 cells [23]. Although the efficiency of the fusion was reduced in all of the HaloTag-attached envelope proteins, all still retained membrane fusion activity (Figure 3C). When we analyzed the fusion activity with the DSP assay [34], better fusion was observed (data not shown). Since the DSP assay relies on the smaller reporter proteins, the presence of the defect of pore dilatation in HaloTag attached mutants was suggested.

#### Topology mapping of gp41 in mammalian cells using HaloTag-specific membrane-impermeable ligands


The membrane-permeable and membrane-impermeable ligands with fluorescent chromophore available for HaloTag were used to examine the location of the attached HaloTag in relation to the cell membrane. Oregon Green (OG) that readily cross the cell membrane labels HaloTag located in both extracellular and intracellular spaces, whereas Alexa Fluor 488 (AF488), a membrane-impermeable ligand, should label HaloTag exposed on the cell surface. When we used the membrane-permeable substrate, OG, all of the 293FT cells transfected with HaloTag-fused truncated Env

**Table 2 Results of GFP quantification**

Vector	Adjusted GFP signal (The number of counts /OD <sub>600</sub> )
optGFP <sub>1-11</sub> /pET-47md	4026.238
mpKMalp2e-gp41-4-GFP	1103.775
mpKMalp2e-gp41-5-GFP	971.453
mpKMalp2e-gp41-6-GFP	828.177
mpKMalp2e-gp41-7-GFP	1018.790
mpKMalp2e-gp41-8-GFP	986.997
mpKmalp2e-GFP	313.958

plasmids (pHIVenv-gp41-4-Halo, pHIVenv-gp41-5-Halo, pHIVenv-gp41-6-Halo, pHIVenv-gp41-7-Halo, and pHIVenv-gp41-8-Halo) were stained by the ligand (Additional File 1; Figure S1). The 293FT cells transfected with pHook-Halo-GPI and pKcTac-Halo were also stained by OG; the fluorescent signal was localized at the rim of the cells (Additional File 1; Figure S1). On the other hand, when we used the membrane-impermeable substrate, AF488, none of the 293FT cells transfected with the plasmids harboring HaloTag-fused Env with C-terminal truncation were stained (Figure 4 pHIVenv-gp41-4 to -8-Halo). As


expected, the 293FT cells transfected with pHook-Halo-GPI were stained by AF488, but the 293FT cells transfected with pKcTac-Halo did not show any fluorescent signal under the same labeling and imaging conditions (Figure 4), verifying the authenticity of this experimental system. These results indicate that the HaloTag attached at positions 4 to 8 of gp41 are located in the cytoplasm of the cells. This result is consistent with the prokaryotic data (Table 2) and suggests that Kennedy sequence and LLP regions are both located in the cytoplasm, supporting the single MSD model of gp41 [11].



### Examination of membrane topology with HaloTag in syncytia formed in 293CD4

As the possibility for a transient topological change of gp41 during membrane fusion has been proposed [16,17], we induced the formation of syncytia in 293CD4 by transfecting a series of Env-HaloTag expression vectors and performed the labeling. All of the syncytia formed after transfecting the expression vector for each Env-HaloTag were positively stained with OG, membrane-permeable ligand, during membrane fusion, confirming the expression of Halo-fused Envs (Additional File 2; Figure S2). When the membrane-impermeable ligand AF488 was used for staining, most of the multinucleated 293CD4 cells expressing various gp41

truncation mutants were not stained (Figure 5). The only exception was the cells transfected with pHIVenv-gp41-5-Halo, in which rare and weak staining of the syncytia were observed (Figure 5). Even the later time points with the similar levels of syncytia formation with pHIVenv-gp41-8-Halo were chosen to compensate the reduced fusion efficiency of pHIVenv-gp41-5-Halo, the staining incidence for pHIVenv-gp41-5-Halo did not increase. The 293CD4 cells transfected with the control plasmids, pHook-Halo-GPI (HaloTag on the cell surface) and pKcTac-Halo (HaloTag in the cytoplasm), showed the results consistent with their expected topological locations (Figure 5 pHook-Halo-GPI and pKcTac-Halo).



**Figure 5 Topological analysis of gp41 in 293CD4 cells.** Images of the cells stained with membrane impermeable ligand, Alexa Fluor 488 (AF488). The staining and image capturing were done at 20 h post transfection. The abbreviations used are same as in Fig. 4. The bar indicates 30 µm.



When the 293CD4 cells transfected with pHIVenv-gp41-5-Halo were stained with the anti-HaloTag antibody without permeabilization procedure, rare events of staining were observed (data not shown). These results suggest that the possibility of sporadic exposure of cytoplasmic domain of gp41 during membrane fusion with pHIVenv-gp41-5-Halo.

#### Augmented membrane permeability by Env-induced membrane fusion

The result shown above for pHIVenv-gp41-5-Halo could be an indication of a rare translocation of the cytoplasmic region of the gp41. The reason why the translocation, if happening, is limited to the truncation at position 5 with a very low incidence was not clear. Since there was no staining for pHIVenv-gp41-4-Halo, we have to assume a hypothetical MSD between the position 4 and 5. This is to assume the Kennedy region to be the hypothetical MSD and is different from the model shown in Figure 1C. The hydrophilic Kennedy sequence is not likely to be an MSD by several prediction algorithms (Table 3). An alternative possibility is that the sporadic staining was due to the induced permeability of membranes in syncytia.

To distinguish the alteration of gp41 topology from membrane permeability induced during membrane fusion, we co-expressed tag-free HIV-1 Env together with Tac-Halo in the same cells. Namely, the pKcTac-Halo, and pHIVenv-gp41-5/pHIVenv-gp41-8 or pHIVenv-CD22-gp41-5/pHIVenv-CD22-gp41-8 (Table 1) were co-transfected simultaneously. We then probed the HaloTag expressed in the cytoplasmic side (see Figure 3A) with AF488, membrane-impermeable ligands. Both 293FT (fusion incompetent) and 293CD4 (fusion competent) cells were used to determine the effect of membrane fusion. The co-transfected 293FT cells were not stained with AF488 (Figure 6 -soluble CD4), whereas these cells were stained with OG (data not shown). The expressions of Env in 293FT cells were confirmed by immunoblotting (Additional file 3; Figure S3). The addition of soluble CD4, which can induce the early conformational change of gp120, did not show any changes in the staining patterns (Figure 6 + soluble CD4).

**Table 3 Computational analyses of possible transmembrane domain**


Program	Region of the predicted membrane-spanning segment (original: 684-706)
TroPred	684-705
TMHMM	678-701
SOSUI_MP1	675-708
SOSUI	683-706

In the case of 293CD4 cells, however, the co-transfected cells (Figure 7 -C34, pHIVenv-gp41-5 or 8 + pKcTac-Halo,) could be clearly stained by AF488 at the site of syncytium (Figure 7 -C34). These staining were not due to the cell death, because some cells labeled with AF488 did not show the staining with propidium iodide (Figure 7 shown in red). The staining with AF488 was abolished when membrane fusion was inhibited by the addition of C34, an inhibitor of six-helix bundle formation (Figure 7 +C34, pHIVenv-gp41-5 or -8 +pKcTac-Halo). These results indicated that the induction of the permeability was dependent on active membrane fusion.

To examine whether the observed membrane permeability during membrane fusion allows antibodies to penetrate membranes, we probed the 3 × FLAG epitope attached to the cytoplasmic portion of the Tac antigen (Tac-FLAG) with the anti-FLAG antibody. The intracellular 3 × FLAG tag was detectable when HIV-1 Env with or without the truncation, pHIVenv-gp41-5 and pHIVenv-gp41-8, respectively, were co-expressed (Figure 8 -C34). Although the staining pattern of each syncytium varies, it seemed that the incidence of the positively stained syncytia was slightly lower than that obtained with the membrane-impermeable ligands shown in Figure 7. When the membrane was permeabilized with detergent prior to antibody staining, all of syncytia were stained well (data not shown). These results suggest both the full-length and truncated Env have the ability to permeabilize the membrane to allow the antibodies to cross the membranes.

#### Augmented membrane permeability is dependent on MSD sequence

Since membrane permeability was induced in the cells transfected with pHIVenv-gp41-5-Halo, the presence of LLPs is not required for the increased permeability. To further characterize the region required for this enhanced permeability we constructed the mutants in which the original gp41 MSD was replaced with the foreign MSD derived from CD22 [27] in the pHIVenv context. Previous reports indicated that the MSD derived from CD22 did not alter the function of HIV-1 Env [27]; however, the replacement seemed to delay the appearance of syncytia when compared with the wild type (see below). We compared these mutants with the HIV-1 Env with the native MSD. In the case of the HIV-1 Env with its native MSD, intracellular HaloTag was detectable with membrane-impermeable AF488 at the earlier time point after co-transfection (16 h post transfection, Figure 7; pHIVenv- gp41-5 and 8). On the other hand, there was minimal staining in cells co-transfected with HIV-1 Env with CD22 MSD at 16 h after transfection (data not shown). At 44 h post transfection when the cells transfected with the native gp41 MSD were almost gone due to



the cell death, some cells transfected with CD22 MSD mutants were stainable with AF488 (Figure 7 -C34, pHIVenv-CD22-gp41-5 or 8 + pKcTac-Halo). Therefore there is a significant difference in the pattern of the staining between the native and CD22 MSDs. At 44 h post transfection, there were more dead cells as indicated by the positive PI staining. These cells were also stained with AF488. There are, however, some syncytia stained only with AF488 for CD22 MSD mutants (Figure 7). Inhibition of the membrane fusion with C34 blocked the staining (Figure 7 +C34). Similar results were obtained if anti-FLAG antibodies were used to detect the FLAG tag located in the cytoplasm. (Figure 8 pHIVenv-CD22-gp41-5 or 8 + pKcTac-FLAG). Taken together, these results indicated that the induction of permeability was membrane fusion-dependent and that the gp41 MSD played some role in the degree of induced permeabilization during membrane fusion.


## Discussion

In this study we examined the membrane topology of the gp41 subunit in two different biological systems.

The truncated gp41 subunit was tagged with the topological reporter protein at the C-terminus (Figure 1, 2, 3). A prokaryotic reporter, GFP [31,32] and mammalian reporter, HaloTag [33], were used. Both reporters enabled us to examine the topology in living cells without the artifacts caused by fixing.

In our prokaryotic system, all of the tested constructs (mpKMalp2e-gp41-4, 5, 6, 7- and 8-GFP) showed stronger GFP fluorescence than the control. This suggested that gp41 had a single MSD that places the Kennedy sequence, LLP-2, LLP-3, LLP-1 and the C-terminus of gp41 in the cytoplasmic side. The analysis with  $\beta$ -lactamase, another topology reporter, which is only active in periplasm produced the data consistent with that of GFP (data not shown). These data are consistent with the results obtained by the currently available several programs for prediction of transmembrane domains (Table 3).

Our analysis of gp41 topology in mammalian cells without membrane fusion (293FT cells) supported the single transmembrane model, concordant with that of




the prokaryotic system. Only sporadic staining with membrane impermeable ligands was observed for pHIVenv-gp41-5-Halo (truncation at position 747 in HXB2 Env) in fusion-competent 293CD4 cells. Since staining for the preceding truncation point, pHIVenv-gp41-4-Halo (truncation at the residue 725 in HXB2), was negative, suggesting an additional MSD between the residue 725 and 747. This region contains about 20 mainly hydrophilic amino acid residues that correspond to the Kennedy sequence. As shown in Table 3 no MSD was predicted in this region by several computational algorithms. So we speculated that there is other reason for the observed apparently contradictory observations.

We examined the possibility of enhanced membrane permeability to account for the staining of putative intracellular regions during membrane fusion. The

intracellularly located HaloTag was labeled using the membrane-impermeable ligand for HaloTag when HIV-1 Env-mediated membrane fusion occurred (Figure 7). Antibodies were also able to stain the intracellular targets in conditions of membrane fusion (Figure 8). Although we cannot completely exclude the possible alternations of the gp41 topology, the multiple MSD model based on the epitope mapping [16,17] needs to be reevaluated carefully given the increased permeability we have observed.

We attempted to map the region(s) of gp41 responsible for increased membrane permeability. Our data suggested that the increased permeability was dependent on active membrane fusion (Figure 7 and 8). It is consistent with several reports of the fusion-dependent induction of membrane permeability in HIV-1 infected cells [35-38].



It is known that the several isolated subdomains of gp41, critical for membrane fusion, have potential to permeabilize the mammalian and the bacterial membranes [39-50]. These include the fusion peptide, the membrane proximate external region, the MSD and the LLPs. Our data of pHIVenv-gp41-5 (Figure 7 and 8) excludes the possibility of the role of LLPs. Our data using MSD replacement mutants pHIVenv-CD22-gp41-5 or pHIVenv-CD22-gp41-8, suggested the MSD affected the level of permeability, but whether the MSD directly affected the permeability or the effect was mediated via the efficiency of the membrane fusion was hard to be determined.

Since our assay relied on the topological reporter proteins attached at the C-termini of truncated gp41 proteins, the possibility of artifacts cannot be excluded. The exact reason why neutralizing epitopes mapped to the

cytoplasmic regions remains unclear. There are at least two possible explanations. First, it is possible that some of the antibodies themselves are intrinsically membrane permeable. Second, permeability that is sufficient to permit antibodies to cross the membrane may be induced by membrane fusion. Although our findings support the latter model, further study is needed to explore whether an alternative topology for gp41 MSD during membrane fusion really takes place and if such a possibility is a general phenomenon for other HIV-1 strains.

### Conclusions

The membrane topology of the gp41 subunit of HIV-1 Env was examined in both prokaryotic and mammalian systems. The topology with a single MSD was supported in both systems. In addition, augmented membrane

permeability was shown to be dependent on both the sequence of MSD and active membrane fusion.

#### List of abbreviations

Env: envelope glycoprotein; HIV-1: human immunodeficiency virus type-1; LLP: lentiviral lytic peptide; MSD: membrane-spanning domain; GFP: green fluorescent protein; GPI: glycosylphosphatidylinositol; FBS: fetal bovine serum; OG: Oregon Green; AF488: Alexa Fluor 488; PI: propidium iodide; PBS: phosphate buffered saline.

#### Acknowledgements

This work was supported by a contract research fund from the Ministry of Education, Culture, Sports, Science and Technology for Program of Japan Initiative for Global Research Network on Infectious Diseases. We thank Dr. Kunito Yoshiike for his critical reading of the manuscript.

#### Additional material

**Additional file 1: Supplemental Fig.1 Detection of HaloTag-attached HIV-1 Env in 293FT cells.** Images of the transfected 293FT cells stained with membrane-permeable ligand, Oregon Green (OG). BF indicates the bright field images. The names of the expression vectors are shown. Mock, mock DNA transfection.

**Additional file 2: Supplemental Fig.2 Detection of HaloTag-attached HIV-1 Env in 293CD4 cells.** Images of the transfected 293CD4 cells stained with membrane permeable ligand, Oregon Green (OG). The nomenclature used are same as Supple Figure 1.

**Additional file 3: Supplemental Fig.3 Expression of HIV-1 Env with its native MSD or foreign CD22MSD in 293FT cells.** The expression of the envelope protein was examined by immunoblotting using the anti-gp120 antibody as described previously [23]. The names of the expression vectors were shown on top. The bands of gp160 and gp120 are indicated.

#### Author details

<sup>1</sup>China-Japan Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing 100101, P. R. China. <sup>2</sup>Research Center for Asian Infectious Diseases, and <sup>3</sup>Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai Minato-ku, Tokyo 108-8639, Japan. <sup>3</sup>Current Address: Department of Pediatrics, Emory University School of Medicine, 2015 uppergate Dr. Atlanta, GA 30322, USA.

#### Authors' contributions

SL, NK, YL and DX performed the experiments. The analysis in the prokaryotic system was done by SL and DX. The work in mammalian system was performed by SL, NK and YL. The study was conceived by ZM. AI supervised the entire work. SL, NK and ZM wrote the manuscript. All authors read and approved the final manuscript.

#### Competing interests

The authors declare that they have no competing interests.

Received: 13 July 2010 Accepted: 30 November 2010

Published: 30 November 2010

#### References

1. Dettenhofer M, Yu XF: Characterization of the biosynthesis of human immunodeficiency virus type 1 Env from infected T-cells and the effects of glucose trimming of Env on virion infectivity. *J Biol Chem* 2001, **276**:5985-5991.
2. Otteken A, Earl PL, Moss B: Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. *J Virol* 1996, **70**:3407-3415.
3. Dash B, McIntosh A, Barrett W, Daniels R: Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion. *J Gen Virol* 1994, **75**(Pt 6):1389-1397.
4. Fenouillet E, Jones IM: The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. *J Gen Virol* 1995, **76**(Pt 6):1509-1514.
5. Eisenberg D, Wesson M: The most highly amphiphilic alpha-helices include two amino acid segments in human immunodeficiency virus glycoprotein 41. *Biopolymers* 1990, **29**:171-177.
6. Kligler Y, Shai Y: A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. *Biochemistry* 1997, **36**:5157-5169.
7. Gawrisch K, Han KH, Yang JS, Bergelson LD, Ferretti JA: Interaction of peptide fragment 828-848 of the envelope glycoprotein of human immunodeficiency virus type I with lipid bilayers. *Biochemistry* 1993, **32**:3112-3118.
8. Srinivas SK, Srinivas RV, Anantharamaiah GM, Segrest JP, Compans RW: Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. *J Biol Chem* 1992, **267**:7121-7127.
9. Viard M, Ablan SD, Zhou M, Veenstra TD, Freed EO, Raviv Y, Blumenthal R: Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. *Biochemistry* 2008, **47**:1977-1983.
10. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ: Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. *Nature* 1985, **313**:450-458.
11. Haffar OK, Dowbenko DJ, Berman PW: Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. *J Cell Biol* 1988, **107**:1677-1687.
12. Yang C, Spies CP, Compans RW: The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. *Proc Natl Acad Sci USA* 1995, **92**:9871-9875.
13. Rowell JF, Stanhope PE, Siliciano RF: Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. *J Immunol* 1995, **155**:473-488.
14. Kennedy RC, Henkel RD, Pauletti D, Allan JS, Lee TH, Essex M, Dreesman GR: Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. *Science* 1986, **231**:1556-1559.
15. Vella C, Ferguson M, Dunn G, Meloen R, Langedijk H, Evans D, Minor PD: Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. *J Gen Virol* 1993, **74**(Pt 12):2603-2607.
16. Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ: A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. *J Gen Virol* 2003, **84**:591-602.
17. Lu L, Zhu Y, Huang J, Chen X, Yang H, Jiang S, Chen YH: Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. *J Biol Chem* 2008, **283**:16723-16731.
18. Yue L, Shang L, Hunter E: Truncation of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein defines elements required for fusion, incorporation, and infectivity. *J Virol* 2009, **83**:11588-11598.
19. Shang L, Yue L, Hunter E: Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. *J Virol* 2008, **82**:5417-5428.
20. Salzwedel K, Johnston PB, Roberts SJ, Dubay JW, Hunter E: Expression and characterization of glycosylphospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. *J Virol* 1993, **67**:5279-5288.
21. Weiss CD, White JM: Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-

- anchored human immunodeficiency virus type 1 envelope glycoprotein. *J Virol* 1993, **67**:7060-7066.
22. Owens RJ, Burke C, Rose JK: Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity. *J Virol* 1994, **68**:570-574.
  23. Miyauchi K, Komano J, Yokomaku Y, Sugiura W, Yamamoto N, Matsuda Z: Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. *J Virol* 2005, **79**:4720-4729.
  24. Miyauchi K, Curran R, Matthews E, Komano J, Hoshino T, Engelman DM, Matsuda Z: Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions. *Jpn J Infect Dis* 2006, **59**:77-84.
  25. Wang J, Kondo N, Long Y, Iwamoto A, Matsuda Z: Monitoring of HIV-1 envelope-mediated membrane fusion using modified split green fluorescent proteins. *J Virol Methods* 2009, **161**:216-222.
  26. Kondo N, Ebihara A, Ru H, Kuramitsu S, Iwamoto A, Rao Z, Matsuda Z: Thermus thermophilus-derived protein tags that aid in preparation of insoluble viral proteins. *Anal Biochem* 2009, **385**:278-285.
  27. Wilk T, Pfeiffer T, Bukovsky A, Moldenhauer G, Bosch V: Glycoprotein incorporation and HIV-1 infectivity despite exchange of the gp160 membrane-spanning domain. *Virology* 1996, **218**:269-274.
  28. Caras IW, Weddell GN, Williams SR: Analysis of the signal for attachment of a glycopospholipid membrane anchor. *J Cell Biol* 1989, **108**:1387-1396.
  29. Cosson P, Lankford SP, Bonifacino JS, Klausner RD: Membrane protein association by potential intramembrane charge pairs. *Nature* 1991, **351**:414-416.
  30. van Genderen H, Kenis H, Lux P, Ungeth L, Maassen C, Deckers N, Narula J, Hofstra L, Reutelingsperger C: In vitro measurement of cell death with the annexin A5 affinity assay. *Nat Protoc* 2006, **1**:363-367.
  31. Drew D, Sjostrand D, Nilsson J, Urbig T, Chin CN, de Gier JW, von Heijne G: Rapid topology mapping of Escherichia coli inner-membrane proteins by prediction and PhoA/GFP fusion analysis. *Proc Natl Acad Sci USA* 2002, **99**:2690-2695.
  32. Duffy EB, Barquera B: Membrane topology mapping of the Na<sup>+</sup>-pumping NADH: quinone oxidoreductase from Vibrio cholerae by PhoA-green fluorescent protein fusion analysis. *J Bacteriol* 2006, **188**:8343-8351.
  33. Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, Wood MG, Learish R, Ohana RF, Urh M, et al: HaloTag: a novel protein labeling technology for cell imaging and protein analysis. *ACS Chem Biol* 2008, **3**:373-382.
  34. Kondo N, Miyauchi K, Meng F, Iwamoto A, Matsuda Z: Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain. *J Biol Chem* 2010, **285**:14681-14688.
  35. Cloyd MW, Lynn WS: Perturbation of host-cell membrane is a primary mechanism of HIV cytopathology. *Virology* 1991, **181**:500-511.
  36. Zhang H, Dornadula G, Alur P, Laughlin MA, Pomerantz RJ: Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. *Proc Natl Acad Sci USA* 1996, **93**:12519-12524.
  37. Gatti PJ, Choi B, Haislip AM, Fermin CD, Garry RF: Inhibition of HIV type 1 production by hygromycin B. *AIDS Res Hum Retroviruses* 1998, **14**:885-892.
  38. Voss TG, Fermin CD, Levy JA, Vigh S, Choi B, Garry RF: Alteration of intracellular potassium and sodium concentrations correlates with induction of cytopathic effects by human immunodeficiency virus. *J Virol* 1996, **70**:5447-5454.
  39. Miller MA, Cloyd MW, Liebmann J, Rinaldo CR, Islam KR, Wang SZ, Mietzner TA, Montelaro RC: Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. *Virology* 1993, **196**:89-100.
  40. Chernomordik L, Chanturiya AN, Suss-Toby E, Nora E, Zimmerberg J: An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. *J Virol* 1994, **68**:7115-7123.
  41. Arroyo J, Boceta M, Gonzalez ME, Michel M, Carrasco L: Membrane permeabilization by different regions of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41. *J Virol* 1995, **69**:4095-4102.
  42. Comardelle AM, Norris CH, Plymale DR, Gatti PJ, Choi B, Fermin CD, Haislip AM, Tencza SB, Mietzner TA, Montelaro RC, Garry RF: A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes. *AIDS Res Hum Retroviruses* 1997, **13**:1525-1532.
  43. Suarez T, Gallaher WR, Agirre A, Goni FM, Nieva JL: Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. *J Virol* 2000, **74**:8038-8047.
  44. Suarez T, Nir S, Goni FM, Saez-Cirion A, Nieva JL: The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. *FEBS Lett* 2000, **477**:145-149.
  45. Brugger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, Krausslich HG: The HIV lipidome: a raft with an unusual composition. *Proc Natl Acad Sci USA* 2006, **103**:2641-2646.
  46. Saez-Cirion A, Arrondo JL, Gomara MJ, Lorizate M, Iloro I, Melikyan G, Nieva JL: Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation. *Biophys J* 2003, **85**:3769-3780.
  47. Saez-Cirion A, Nir S, Lorizate M, Agirre A, Cruz A, Perez-Gil J, Nieva JL: Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. *J Biol Chem* 2002, **277**:21776-21785.
  48. Apellaniz B, Nir S, Nieva JL: Distinct mechanisms of lipid bilayer perturbation induced by peptides derived from the membrane-proximal external region of HIV-1 gp41. *Biochemistry* 2009, **48**:5320-5331.
  49. Huarte N, Lorizate M, Kunert R, Nieva JL: Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies. *FEBS Lett* 2008, **582**:3798-3804.
  50. Dimitrov AS, Rawat SS, Jiang S, Blumenthal R: Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. *Biochemistry* 2003, **42**:14150-14158.

doi:10.1186/1742-4690-7-100

Cite this article as: Liu *et al.*: Membrane topology analysis of HIV-1 envelope glycoprotein gp41. *Retrovirology* 2010 **7**:100.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

